Product Images Elepsia Xr

This text appears to be a medical equation for estimating creatinine clearance rate based on the age, weight, and height of a patient, along with their serum creatinine levels. It provides a formula for male and female patients. However, without a full understanding of the medical context and purpose of the equation, it is difficult to provide a more detailed or accurate description.*

The text describes a figure showing the responder rate, in terms of percentage reduction from baseline, in Study 2. The x-axis shows the percentage of patients, while the y-axis ranges from 0% to 45%. Different treatments are represented in the graph, including Placebo, immediate-release Levetiracetam at a dosage of 1,000 mg/day, and immediate-release Levetiracetam at a dosage of 3,000 mg/day. The figure indicates that the responder rate was statistically significant versus placebo.*

This is a graph (Figure 2) showing the Responder Rate in Study 3, Period A. The Responder Rate is a measure of the percentage of patients who achieved a 250% reduction from baseline. The graph displays the percentage of patients on the y-axis and differing percentages of response on the x-axis. There are three treatment groups: placebo, immediate-release Levetiracetam 1,000 mg/day, and immediate-release Levetiracetam 2,000 mg/day. The percentage of responders for each group is marked by a dot on the corresponding percentage line. The group treated with immediate-release Levetiracetam 2,000 mg/day had a statistically significant higher percentage of responders than the placebo group.*

This is a chart showing the Responder Rate, which is the percentage of patients with a 50% reduction from baseline, in a study labeled "Study 4". The data is presented as percentages on the y-axis with 5% increments up to 45%. The x-axis has no labels but shows two data points: 14.4% for the Placebo group (N=104) and 39.4% for the Immediate-release Levetiracetam group at 3,000 mg/day (N=180).*

The figure shows the responder rate of reduction in seizure frequency from baseline in Study 5. The percentage of patients achieving a 50% reduction is displayed on the y-axis, ranging from 0% to 50%. The x-axis displays the two treatment groups: placebo (N=97) and immediate-release Levetiracetam (N=101). The immediate-release Levetiracetam group had a responder rate of 44.6%, which was statistically significant compared to the placebo group's responder rate of 19.6%.*

This is a package insert for Elepsia XR (levetiracetam) extended-release tablets. The usual dosage is not available. The tablets should be stored between 15°C and 30°C (59°F and 86°F) and dispensed in a tight, light-resistant container with a child-resistant closure. The tablets should be swallowed whole and not chewed, broken, spit, or crushed. The package contains 500 tablets and a medication guide for each patient. Pharmacists are advised to dispense the medication with the guide.*